CANVAS Trial Results: Better For Janssen, Lilly Or the SGLT2 Class?

Johnson & Johnson subsidiary Janssen Pharmaceutical Cos. reported a 14% reduction in the risk of major cardiovascular events for Invokana (canagliflozin) in the CANVAS outcomes trials, which was the same MACE reduction observed in the EMPA-REG trial for competing SGLT2 inhibitor Jardiance (empagliflozin), but it may be too early to declare the drugs' cardiovascular benefits – and Invokana's amputation risk – a class effect.

Investigators who talked about the CANVAS results on June 12 at the American Diabetes Association (ADA) 77th Scientific Sessions in San Diego had a generally positive view of the results, but stopped short of calling the MACE risk reductions seen in